13 Inflammatory Bowel Disease Clinical Trials in Lancaster, CA (2026)

Q: How do I join a clinical trial in Lancaster?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Lancaster research site will contact you.

Recruiting Inflammatory Bowel Disease Studies in Lancaster

NCT07697456Recruiting

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any ...

Lancaster, CAPHASE22,000 participantsAbbVie

View Study Details

NCT06430801Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1...

Lancaster, CAPHASE31,200 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07196722Recruiting

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term ...

Lancaster, CAPHASE21,092 participantsJanssen Research & Development, LLC

View Study Details

NCT07184931Recruiting

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participant...

Lancaster, CAPHASE3980 participantsSanofi

View Study Details

NCT07184996Recruiting

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely...

Lancaster, CAPHASE3980 participantsSanofi

View Study Details

NCT07196748Recruiting

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely ac...

Lancaster, CAPHASE3882 participantsJanssen Research & Development, LLC

View Study Details

NCT07012395Recruiting

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficac...

Lancaster, CAPHASE2645 participantsSpyre Therapeutics, Inc.

View Study Details

NCT06819878Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) i...

Lancaster, CAPHASE3600 participantsHoffmann-La Roche

View Study Details

NCT06819891Recruiting

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately...

Lancaster, CAPHASE3425 participantsHoffmann-La Roche

View Study Details

NCT06226883Recruiting

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately...

Lancaster, CAPHASE2385 participantsMorphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

View Study Details

NCT07186101Recruiting

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely activ...

Lancaster, CAPHASE2252 participantsEli Lilly and Company

View Study Details

NCT06979336Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventiona...

Lancaster, CAPHASE2224 participantsGenentech, Inc.

View Study Details

NCT06958536Recruiting

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared w...

Lancaster, CAPHASE299 participantsSanofi

View Study Details

About Inflammatory Bowel Disease Clinical Trials in Lancaster

Inflammatory bowel disease (IBD) encompasses chronic inflammatory conditions of the gastrointestinal tract, primarily Crohn's disease and ulcerative colitis. It affects millions worldwide and can cause debilitating symptoms. Treatment includes anti-inflammatory drugs, immunosuppressants, biologics, and surgery.

There are currently 13 inflammatory bowel disease clinical trials recruiting participants in Lancaster, CA. These studies are seeking a combined 9,764 participants. Research is being sponsored by AbbVie, Merck Sharp & Dohme LLC, Janssen Research & Development, LLC and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Inflammatory Bowel Disease Clinical Trials in Lancaster — FAQ

Are there inflammatory bowel disease clinical trials in Lancaster?

Yes, there are 13 inflammatory bowel disease clinical trials currently recruiting in Lancaster, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Lancaster?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Lancaster research site will contact you about next steps.

Are clinical trials in Lancaster free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Lancaster studies also compensate for your time and travel.

What inflammatory bowel disease treatments are being tested?

The 13 active trials in Lancaster are testing new therapies including novel drugs, biologics, and treatment approaches for inflammatory bowel disease.

Data updated October 17, 2026 from ClinicalTrials.gov